Dieter E. Kaufmann | Medicinal Chemistry | Best Researcher Award

Published on by Academic Awards

Prof. Dr. Dieter E. Kaufmann | Medicinal Chemistry | Best Researcher Award

Technical University of Clausthal | Germany

Prof. Dr. Dieter E. Kaufmann is a distinguished organic chemist whose research bridges fundamental synthetic chemistry and applied materials science. His work focuses on the design and synthesis of heterocyclic compounds, polyhalogenated nitrobutadienes, and functionalized benzoates with applications in medicinal chemistry, sustainable materials, and energy systems. He has contributed extensively to the chemical modification of renewable resources, including wood, for enhanced durability, hydrophobicity, and flame retardancy, as well as to the development of organic redox flow batteries. With over 128 publications, 3,676 citations, and an h-index of 30, his research demonstrates high scientific impact, innovation, and interdisciplinary collaboration across organic synthesis, catalysis, and green chemistry.

Profile: Scopus | Orcid 

Featured Publications

  • Kaufmann, D. E., et al. (2025). Synthesis and microbiological activities of 3-nitropyrazolo-[1,5-d][1,2,4]triazin-7(6H)-ones and derivatives. Molecules, 2025.

  • Kaufmann, D. E., et al. (2025). Synthesis, characterization and application of thioindigosulfonic acids as electrolytes in an aqueous organic redox flow battery. ChemElectroChem, 2025.

  • Kaufmann, D. E., et al. (2023). A new way to 2,3,4-trisubstituted benzo[h]quinolines: Synthesis, consecutive reactions and cellular activities. Molecules, 2023.

  • Kaufmann, D. E., et al. (2023). Chemistry of polyhalogenated nitrobutadienes, 19: Synthesis of new types of compounds modulating the biological activity of Type I interferons (IFN-I). Arkivoc, 2023.

  • Kaufmann, D. E., et al. (2022). Intramolecular phosphine-promoted Knoevenagel based redox-reaction. Molecules, 2022.

  • Kaufmann, D. E., et al. (2022). Chemistry of polyhalogenated nitrobutadienes, 17: Efficient synthesis of persubstituted chloroquinolinyl-1H-pyrazoles and evaluation of their antimalarial, anti-SARS-CoV-2, antibacterial, and cytotoxic activities. Beilstein Journal of Organic Chemistry, 2022.

  • Kaufmann, D. E., et al. (2021). Surface tuning of wood via covalent modification of its lignocellulosic biopolymers with substituted benzoates: A study on reactivity, efficiency, and durability. ACS Omega, 2021.

  • Kaufmann, D. E., et al. (2021). Durable modification of wood by benzoylation—Proof of covalent bonding by solution state NMR and DOSY NMR quick-test. Polymers, 2021.

  • Kaufmann, D. E., et al. (2021). Chemical improvement of surfaces. Part 6: Enhanced flame retardancy of Scots pine sapwood by covalent modification with phosphorus and boron functionalized benzoates. Holzforschung, 2021.

  • Kaufmann, D. E., et al. (2021). Surface tuning of wood through chemical modification for enhanced performance and stability. Holzforschung, 2021.

Jing Nie | Medicinal Chemistry | Best Researcher Award

Published on by Academic Awards

Ms. Jing Nie | Medicinal Chemistry | Best Researcher Award

Ms. Jing Nie | Shandong Second Provincial General Hospital | China

Ms. Jing Nie serves as the Head of Scientific Research in the Department of Pharmacy at Shandong Second Provincial General Hospital and holds the position of Associate Chief Pharmacist. She actively contributes to the advancement of pharmaceutical sciences through her leadership roles in various professional committees, including the Shandong Provincial Hospital Association’s Digital and Intelligent Pharmacy Committee, the Pediatric Rational Drug Use Committee of the Shandong Pharmacists Association, and the Otolaryngology Pharmacy Committee of the Shandong Pharmaceutical Society. She is also a core member of the Rheumatology Committee of the Jinan Association of Integrated Traditional Chinese and Western Medicine, the Antitumor Drug Committee of the Shandong Pharmaceutical Society, the Tumor Pharmacy Branch of the Shandong Anti-Cancer Association, and the Internet Plus Pharmacy Services Committee. Her research focuses on hospital pharmacy, artificial intelligence, pharmacoeconomics, and antitumor drug development. She has published extensively, secured patents, developed software, and led multiple provincial and collaborative projects while contributing to numerous national-level studies.

Publication Profile

Scopus

Education

Ms. Jing Nie earned her doctoral degree in pharmacy, equipping her with a strong academic foundation to contribute to both scientific research and clinical pharmacy practice. Her education combined rigorous theoretical learning with extensive research experience, allowing her to specialize in the integration of hospital pharmacy with advanced technologies such as artificial intelligence and pharmacoeconomics. During her doctoral training, she focused on evidence-based approaches to optimize drug therapy and explored the mechanisms and applications of antitumor drugs. Her academic journey not only strengthened her technical expertise but also instilled in her a deep commitment to innovation, patient safety, and rational drug use. She has built upon her formal education through continuous professional development, actively engaging with academic societies, conferences, and specialized committees that broaden her knowledge and keep her at the forefront of evolving pharmaceutical sciences. Her educational background remains the cornerstone of her contributions to research and practice.

Experience

Ms. Jing Nie has extensive professional experience as the Head of Scientific Research in the Department of Pharmacy at Shandong Second Provincial General Hospital, where she also serves as Associate Chief Pharmacist. Her experience includes leadership and active participation in multiple prestigious committees, such as those dedicated to digital pharmacy, rational pediatric drug use, otolaryngology pharmacy, rheumatology, and oncology. She has played a key role in advancing pharmaceutical sciences by bridging hospital pharmacy with innovative fields like artificial intelligence and pharmacoeconomics. Her experience is further reflected in her strong publication record, where she has authored and co-authored more than twenty scientific papers, many in high-impact journals. She has successfully applied her expertise to provincial-level projects, cross-disciplinary collaborations, and has contributed significantly to national-level studies. In addition, her practical work includes obtaining multiple patents and software copyrights, reinforcing her ability to translate scientific innovation into practical applications that benefit patients and the healthcare system.

Research Focus

Ms. Jing Nie’s research focus lies at the intersection of pharmaceutical sciences, oncology, and innovative therapeutic strategies. Her work on the advances of HDAC dual inhibitors in breast cancer treatment highlights her commitment to exploring novel drug mechanisms and targeted therapies in oncology. By investigating epigenetic regulation through HDAC inhibition, she contributes to the development of more effective treatments for breast cancer patients, bridging basic research with clinical applications. Beyond oncology, her broader focus includes hospital pharmacy, pharmacoeconomics, artificial intelligence in drug management, and rational drug use. This multidisciplinary approach allows her to integrate clinical practice with cutting-edge research, addressing both the economic and therapeutic aspects of patient care. Her emphasis on anti-tumor drug development, combined with her role in scientific committees and leadership positions, reflects a holistic vision of improving healthcare outcomes through innovation, collaboration, and translational research. Ms. Nie’s focus is well aligned with advancing precision medicine and modern pharmacy.

Publication Top Notes

Advances of HDAC dual inhibitors in breast cancer treatment

Conclusion

Ms. Jing Nie is highly suitable for the Research for Best Researcher Award, given her impactful contributions to pharmaceutical sciences, leadership roles, and innovation in anti-tumor drug research and artificial intelligence. With strategic international engagement and clinical translation of her work, she has the potential to become a globally recognized leader in hospital pharmacy research.